Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
$5.68
$0.00(0.00%)
At close: 4:00 PM EST
$5.68
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.25 - $13.68
Previous CloseN/A
Volume524.53K
Average Volume (3M)665.15K
Market Cap
$311.82M
Enterprise Value$228.35M
Total Cash (Recent Filing)$86.96M
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Mar 26, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding54,898,304
10 Day Avg. Volume589,789
30 Day Avg. Volume665,147
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)4.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.17
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-246.33
Enterprise Value/Ebitda-11.01
Forecast
1Y Price Target
$19.00Price Target Upside234.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPositive Phase 3 topline data showing a 30% reduction in disease recurrence for localized prostate cancer supports a clear therapeutic role for CAN-2409 and strengthens adoption prospects among clinicians.
Manufacturing And Commercial ReadinessScaled commercial manufacturing capacity with established viral and cell banks plus comparability testing improves the ability to meet regulatory chemistry, manufacturing and controls expectations and to supply commercial demand if approved.
Regulatory PathwayAlignment with the FDA on comparability analysis and an SPA-supported study design streamlines the BLA submission route for CAN-2409, reducing the need for additional clinical bridging work.
Bears Say
Financing RiskA recent debt financing reduces immediate cash pressure but may not eliminate the need for future capital raises, creating potential dilution risk and uncertainty around program timelines.
Pipeline ConcentrationPausing development of CAN-2409 in borderline resectable pancreatic cancer narrows program diversification and could delay realization of value from that indication.
Safety And Treatment Landscape RiskEvidence linking androgen deprivation therapy to higher cardiovascular event risk could complicate treatment comparisons and influence clinician and payer assessments of new prostate cancer therapies.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $4.25 and its highest was $13.68 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $311.82M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 36 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.025.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 54,898,304 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went down -6.301%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (234.51% Upside)
$19.00 (234.51% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.60%
12-Months-Change
Fundamentals
Return on Equity
-70.17%
Trailing 12-Months
Asset Growth
335.00%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$19.00
▲(234.51% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
19.77% Insiders
18.07% Mutual Funds
3.04% Other Institutional Investors
51.68% Public Companies and
Individual Investors